NLRP3 has arisen as a target of interest for Parkinson’s disease (PD) given increased levels seen in patient brain and preclinical studies showing inhibition of NLRP3 decreases pathology and motor deficits in preclinical models of PD. A number of models have been used in preclinical studies of NLRP3 in PD. In this overview document you will find a summary of those that are commonly used. Please note, this list is not comprehensive—others may be suitable for your research.